Turn this list into pipeline.
Biotech Companies in Birmingham: 67 Active Firms (2026)
Biotech companies in Birmingham develop biological research tools, diagnostics and therapeutics for healthcare and industrial markets across the West Midlands.
Commercial demand tends to sit with translational R&D teams, laboratory operations, quality and regulatory functions, and business-development buyers inside healthcare, research, pharmaceutical and industrial biology organisations. Birmingham-area suppliers in this cohort usually look more like specialist product-and-service businesses than pure platform plays: validation projects, assay development, fee-for-service work, licensing discussions and staged supply agreements sit alongside longer product-development cycles. The likely buyer is technical and evidence-led, often needing credible quality systems before procurement moves beyond pilot work. Engagements are therefore relatively high-touch, with lower-mid-market budgets, narrow use cases and a sales motion shaped by scientific proof rather than volume-led demand generation.
Read more
Birmingham has 67 actively trading biotech companies in this list, making the local market a specialist West Midlands cluster rather than a broad national-scale base. Reported employment across the cohort is 198 staff, which points to a company population dominated by lean commercial and technical teams. That profile fits a market where research services, early product validation and regulated development work can be carried by small groups, while only a narrow tail appears to have moved into larger revenue bands. For researchers, the practical read is a compact target universe: enough firms for pattern-spotting, but not enough to treat Birmingham as a standalone proxy for UK biotech.
Biotech work in the UK sits within the life-sciences regulatory framework, with the MHRA setting standards, evaluating new treatments, approving clinical trial applications and overseeing post-authorisation safety through pharmacovigilance. Clinical trials have to satisfy good clinical-practice standards, ethics review and informed-consent requirements, so evidence generation is not a late-stage administrative task for firms developing regulated health products. Market access can add another gate where health technology assessment bodies review approved medicines before routine public reimbursement. Sector bodies also emphasise a market structure in which equity finance is concentrated in larger rounds, often involving US capital, rather than spread evenly across every early-stage company.
Early-commercial weight appears likely to keep shaping the Birmingham cohort: many firms are better read as specialist scientific businesses moving through evidence, validation and partner-led routes to market, rather than volume sellers. Scale-up scarcity tends to matter more than company formation alone, because regulated development rewards patient capital, experienced quality functions and access to clinical or industrial partners. Consolidation may therefore come through partnerships, service extensions and licensing rather than wholesale local roll-ups. The firms that progress are likely to be those that can turn research credibility into repeatable regulated workflows without carrying more infrastructure than their sales pipeline can support.
67
Active firms
2026
2
Over £5M turnover
visible larger operators
22
Since 2022
new incorporations
Key facts
About 2% of the trading cohort reports turnover above £5M (2 of 67 firms) — the rest sits below that revenue band.
32% of the cohort was incorporated since 2022 (22 firms), so a sizeable share is in its first few filing cycles.
Clinical-facing biotech in the UK sits under MHRA oversight, including clinical trial applications, marketing authorisations and pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements.
The UK life-sciences industry generated £146.9 billion in turnover in 2023/2024, with biopharmaceutical activity accounting for £98.9 billion.
UK biotech companies raised £3.5 billion in equity investment in 2024, a 94% increase on the previous year but below £4.5 billion in 2021.
UK government indicators placed the UK second for health R&D budget allocation as a percentage of GDP in 2021 and third for life-sciences equity finance in 2023, behind the USA and China.
Top Birmingham biotech companies
Informed Genomics Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies next‑generation sequencing (NGS) panels, liquid biopsy kits, and cfDNA sample collection and extraction products for genomic research and clinical oncology. Also provides…
Serves genomic healthcare professionals, clinical laboratories, oncology teams and research organisations working in cancer, hereditary disease and translational genomics.
Financial Health
StrongStrong
Location
MIRZYME THERAPEUTICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostics and therapeutics for pregnancy complications, particularly preeclampsia. Uses blood test data and a digital diagnostic algorithm to predict risk during pregnancy and is…
Targets pregnant women at risk of preeclampsia or fetal growth restriction, as well as clinicians, maternity care providers and healthcare systems involved in prenatal care.
Financial Health
DistressedDistressed · -62% CAGR over 4y
Location
Apto-Gen Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures enzymes and molecular biology reagents for PCR, qPCR, NGS and isothermal amplification. Supplies lyophilisation‑compatible reagents and customised solutions for diagnostic…
Serves B2B life science, healthcare and biotechnology customers, including human and animal diagnostics companies, molecular test/device developers, and food and environmental biotechnology…
Financial Health
StrongStrong · Growing, Hiring · 22% CAGR over 4y
Location
VAL PRO LIMITED
Trajectory
2y · 2022–NowFinancial sub-scores
Computed from 2 filingsProvides validation, monitoring, and calibration solutions for life sciences and regulated manufacturing. Supplies wireless data loggers, sensors, and validation software, and delivers services…
Serves regulated B2B organisations in biotech, pharmaceutical, cell and gene therapy, healthcare and food manufacturing, particularly quality, validation, calibration and operations teams managing…
Financial Health
WeakWeak · Hiring · 23% CAGR over 2y
Location
CELENTYX LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research services in human immunology, conducting in vitro assays using patient and healthy donor cells and tissues. Supports drug research in immuno-oncology, autoimmunity,…
Serves pharmaceutical, biotechnology and life sciences research teams developing therapies in immuno-oncology, autoimmunity, inflammation, fibrosis and neuroinflammation.
Financial Health
StableStable · -65% CAGR over 4y
Location
MICROPOLE FABRICATION LTD
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
StableStable
Location
Ecoprocess Analytica Ltd
Trajectory
1y · 2025–NowFinancial Health
Insufficient historyInsufficient history
Location
ESSESYSTEMS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
ASTON MEDICAL TECHNOLOGY LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
DistressedDistressed · 0% CAGR over 2y
Location
Wave Life Sciences
Develops RNA‑based therapeutics using proprietary chemistry and RNA‑targeting technologies. Conducts research, clinical development and manufacturing of medicines for genetic and metabolic diseases…
Serves patients and families affected by serious rare and common diseases, including Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease and obesity, plus healthcare and…
Location
CONVIRON EUROPE LTD.
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDesigns and manufactures controlled‑environment plant growth chambers, walk‑in growth rooms, and custom environmental rooms for plant research and plant‑derived pharmaceutical production. Also…
Serves plant science researchers, universities, research institutes, plant-derived pharmaceutical companies, and glasshouse operators with controlled-environment cultivation needs.
Financial Health
StrongStrong · Hiring · 6% CAGR over 4y
Location
Hydrogel Healthcare Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy
Location
Fp Biogenic Ltd
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · -50% CAGR over 1y
Location
ASK PHARMA DEVELOPMENT LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable
Location
VIROSENSE HEALTH LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed
Location
Birmingham Biotech Ltd
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StableStable · 0% CAGR over 3y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · -10% CAGR over 4y
Location
ZIMMER AND PEACOCK LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops and manufactures electrochemical biosensors and sensing systems for point‑of‑need and wearable applications. Provides contract research covering assay design, sensor fabrication,…
Serves B2B R&D teams, device makers and research organisations developing electrochemical biosensor products, including point-of-need, wearable, food and beverage, and health-tech applications.
Financial Health
StableStable · -48% CAGR over 2y
Location
Chromatwist Limited
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies large Stokes shift fluorescent dyes, probes and chemical precursors for scientific imaging applications. Products are used in flow cytometry, multiphoton microscopy and…
Serves life science and materials research customers, including flow cytometry and multiphoton microscopy users in healthcare, biotech, academic and industrial labs, plus chemical synthesis and…
Financial Health
StrongStrong · Hiring · 12% CAGR over 3y
Location
Histofy Ltd
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops artificial intelligence software for computational pathology, focusing on tissue image analysis for diagnostics, prognostics, and research. Products include tools for mitosis profiling,…
Serves pathology labs, healthcare providers, pharmaceutical researchers and toxicologic pathology teams involved in tissue-based diagnostics, prognostics, cancer assessment and drug development.
Financial Health
StableStable
Location
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and provides liquid biopsy blood tests for cancer screening, diagnosis, treatment guidance and disease monitoring. Analyses circulating tumour cells and molecular biomarkers to support…
Serves people concerned about cancer, including asymptomatic individuals seeking screening, symptomatic patients needing diagnosis, and cancer patients and caregivers seeking treatment guidance,…
Financial Health
WeakWeak · -21% CAGR over 3y
Location
CYTECOM LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostic technology for detecting viable bacteria in clinical samples. Uses optical electrophysiology combining fluorescence microscopy and electrical stimulation to distinguish living and…
Sells to healthcare and diagnostics organisations needing rapid bacterial infection testing, likely including hospitals, clinical laboratories and antibiotic stewardship teams addressing…
Financial Health
WeakWeak · Hiring · 19% CAGR over 4y
Location
MEDHERANT LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops transdermal drug delivery patches using proprietary TEPI Patch technology that delivers drugs through solvent‑free adhesive systems. Focuses on therapies including a testosterone patch for…
Targets pharmaceutical and healthcare partners, investors, and women’s health markets, with end users including postmenopausal women needing hormone therapy and patients in areas such as pain relief.
Financial Health
StableStable · Hiring · 8% CAGR over 3y
Location
QBIOTIX DEVELOPMENTS LTD
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops nucleic acid assays and sample preparation methods designed to improve detection of microbial organisms in laboratory testing, supporting diagnostics, research, and microbial analysis…
Sells to businesses and organisations needing microbial detection, likely including laboratories, diagnostics providers, and healthcare or life sciences teams using nucleic acid testing and sample…
Financial Health
StableStable · -71% CAGR over 3y
Location
Tagomics Ltd
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops epigenomic and multiomic profiling technology for disease research and diagnostics. Uses sequencing, bioinformatics and machine learning to identify genetic, epigenetic and fragmentomic…
Targets B2B life-science and healthcare organisations, including clinical diagnostics labs, genomics researchers and industry partners developing disease profiling and cancer detection applications,…
Financial Health
StrongStrong · Hiring · 77% CAGR over 2y
Location
OVO BIOMANUFACTURING LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops software and technical approaches for viral vaccine manufacturers to monitor and manage defective interfering particles during virus production, helping optimise viral yields in live…
Serves B2B viral vaccine manufacturers, including biopharmaceutical companies producing established or developing live attenuated and inactivated vaccines for human and animal health.
Financial Health
StrongStrong
Location
NEUROSOLUTIONS LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research services for biopharmaceutical companies, conducting electrophysiological and behavioural studies in translational neuroscience. Supports preclinical drug discovery using…
Serves biopharmaceutical companies, from biotech start-ups to multinational pharmaceutical firms, particularly R&D teams involved in neuroscience, preclinical drug discovery and translational…
Financial Health
WeakWeak · 0% CAGR over 2y
Location
CLENT LIFE SCIENCE LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsSupplies molecular biology reagents, PCR and qPCR master mixes, DNA/RNA extraction kits, diagnostic test kits, and laboratory instruments for life science research and clinical diagnostics, including…
Serves B2B life science customers, including molecular biology researchers, university and commercial labs, diagnostic laboratories, and clinical pathology teams.
Financial Health
WeakWeak · Hiring · 41% CAGR over 2y
Location
NANOSYRINX LTD
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops synthetic biology technology for targeted intracellular delivery of biological drugs. Engineers bacterial nanomachines (“nanosyringes”) to transport proteins, peptides and other biologic…
Serves biopharmaceutical and drug development organisations working on biologic therapeutics, especially teams targeting intracellular delivery and difficult-to-drug disease biology.
Financial Health
StrongStrong · Hiring · 20% CAGR over 2y
Location
REGULATORY SCIENTIFIC AND HEALTH SOLUTIONS LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research and regulatory consulting services for pharmaceutical and biotechnology companies, including clinical development support, clinical data management, biostatistics,…
Sells to global pharmaceutical and biotech companies, as well as medical device developers, needing regulatory, clinical development, data, market access and health economics support across the drug…
Financial Health
StrongStrong · Hiring · 22% CAGR over 2y
Location
MIIR LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
KAPPA PHARMACEUTICALS LIMITED
Trajectory
3y · 2023–NowFinancial Health
Insufficient historyInsufficient history
Location
RAINMEDICAL LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StableStable · -68% CAGR over 4y
Location
STRIDEZ LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak
Location
ATMOSPHARMA LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable
Location
THERAPORT LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
StableStable
Location
SAFE WASTE TECHNOLOGY LIMITED
Trajectory
3y · 2022–NowFinancial Health
Insufficient historyInsufficient history
Location
SEVCO 5023 LIMITED
Trajectory
3y · 2023–NowFinancial Health
Insufficient historyInsufficient history
Location
Intravitals Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
MICA BIOSYSTEMS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · -68% CAGR over 4y
Location
METS LABORATORIES UK LTD
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsFinancial Health
DistressedDistressed · 0% CAGR over 1y
Location
GIFFORD BIOSCIENCE LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · -63% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak · -88% CAGR over 2y
Location
Unlock all 67 leads
Showing 43 of 67 — +24 more with verified decision-maker contacts, live data, and CRM sync.
How Birmingham biotech companies work and how to sell to them
What they do
Revenue usually comes from a mix of project fees, milestone-based R&D, laboratory service work, licence options and staged supply agreements. Birmingham biotech firms may package assay validation, sample analysis, biological materials, diagnostic development or bioprocess support as discrete engagements before any longer commercial contract is agreed. Pricing is often scoped around technical workplans: set-up fees, day rates, per-sample charges, batch pricing or milestone payments tied to delivery of usable evidence. Where intellectual property is involved, suppliers may pursue licence income, royalties or collaboration economics, but many still rely on service revenue while products move through validation and regulatory readiness.
Who they sell to
Buyers are usually technical teams inside healthcare, research, pharmaceutical, industrial biology and public-sector life-sciences organisations. The first conversation often sits with heads of R&D, laboratory managers, clinical operations leads, quality directors or business-development teams, with finance and procurement joining once a pilot looks credible. Typical contracts are not impulse purchases; sales cycles tend to run over months, because buyers need scientific fit, quality documentation, supplier due diligence and a clear route from pilot to repeat use. Procurement is most often direct and relationship-led, although larger institutions may push work through approved-supplier lists, framework-style purchasing or formal RFP processes.
What they buy
Most Birmingham biotech firms tend to spend on laboratory operations, quality management, regulatory support and commercial systems before they buy broad back-office tooling. Useful categories include electronic lab notebooks, inventory and sample tracking, document control, audit preparation, data capture, secure file storage, CRM, grant and project accounting, specialist insurance, intellectual-property advice and outsourced finance. Firms with wet-lab activity may also buy equipment maintenance, facilities support, waste handling, cold-chain logistics and recruitment for scientific, quality and commercial roles. Marketing spend is usually selective: technical content, conference activity, partner outreach and account-based prospecting matter more than volume advertising.
Why and how to sell to them
Buying intent tends to appear when a biotech firm moves from ad hoc research work into repeatable delivery: a new quality hire, a regulatory workstream, a first larger customer, a lab expansion, a funding event or preparation for an MHRA-facing milestone can all change the purchasing queue. Common pain points are documentation burden, slow validation cycles, limited commercial bandwidth and the need to reassure technical buyers without overbuilding process. Outbound messages usually land better when they speak to evidence, risk reduction and fit with existing laboratory workflows, rather than general productivity claims.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Birmingham
Related directories
Frequently asked questions
How many biotech companies are there in the Birmingham?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Birmingham?↓
What do biotech companies in the Birmingham actually do?↓
How does Birmingham biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Birmingham?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 67 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.